Quest Diagnostics currently trades with a PE to growth ratio of 1.94, based on Jul 31, 2026 data. Dividing the 24.42 PE ratio by the 12.6% earnings growth rate produces this figure. Relative to the 1.53 average from the past four quarters, the PEG ratio is up by 27%.
Historically, Quest Diagnostics has a PEG ratio averaging 1.86 across the last nine years. At 1.94, today's PEG ratio sits 4.3% more than its historical average. The nine years high came in the Sep 2017 quarter at 8.33, reflecting peak valuation relative to growth. The bottom was reached in the Jun 2021 quarter at 0.04, suggesting attractive value relative to growth during that period.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 1.4 | 19.56 | 14% |
| 2024 | 7.76 | 19.39 | 2.5% |
| 2023 | N/A | 18.17 | -6.3% |
| 2022 | N/A | 19.31 | -48.9% |
| 2021 | 0.22 | 10.92 | 49.2% |
| 2020 | 0.17 | 11.22 | 67% |
| 2019 | 0.93 | 16.79 | 18% |
| 2018 | N/A | 15.45 | -4.3% |
| 2017 | 0.76 | 17.49 | 22.9% |
| 2016 | N/A | 20.07 | -6.9% |
| 2015 | 0.51 | 14.46 | 28.5% |
| 2014 | N/A | 17.51 | -31.4% |
| 2013 | 0.16 | 9.59 | 59.9% |
| 2012 | 0.91 | 16.7 | 18.3% |
| 2011 | N/A | 19.68 | -27.7% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Jun 2026 | 1.76 | 22.22 | 12.6% |
| Mar 2026 | 1.47 | 21.37 | 14.5% |
| Dec 2025 | 1.4 | 19.56 | 14% |
| Sep 2025 | 1.48 | 22.06 | 14.9% |
| Jun 2025 | 1.64 | 21.21 | 12.9% |
| Mar 2025 | 3.3 | 21.12 | 6.4% |
| Dec 2024 | 7.76 | 19.39 | 2.5% |
| Sep 2024 | 1.95 | 20.64 | 10.6% |
| Jun 2024 | 2.61 | 18.25 | 7% |
| Mar 2024 | 2.03 | 17.68 | 8.7% |
| Dec 2023 | N/A | 18.17 | -6.3% |
| Sep 2023 | N/A | 17.92 | -34.6% |
| Jun 2023 | N/A | 20.05 | -43% |
| Mar 2023 | N/A | 20.42 | -54.9% |
| Dec 2022 | N/A | 19.31 | -48.9% |
When comparing to historical data, DGX's PEG ratio sits above the 10-year average, but it is lower than the 3 and 5-year averages.
With a PEG of 1.94, DGX stands higher than the Healthcare sector and the industry average. Looking at the Healthcare sector average of 0.56, Quest Diagnostics's PEG is 246% higher.
Relative to its peer stocks LH and QGEN, DGX's PEG ratio is higher.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| QGEN Qiagen NV | 0.07 | $8.78B |
| LH Laboratory Corp Of America Holdings | 0.9 | $25.42B |
| DGX Quest Diagnostics Inc | 1.94 | $25.7B |
| NEO Neogenomics Inc | N/A | $2.05B |
According to Jul 31, 2026 figures, DGX's PEG ratio stands at 1.94.
DGX's 3-year PEG ratio average is 2.54.
DGX's 5-year PEG ratio average is 2.02.
DGX's PEG ratio topped out at 8.33 during the Sep 2017 quarter - the highest in nine years.
Compared to the 9-year average, DGX's PEG ratio stands 4.3% higher.
Computing the PEG ratio involves dividing the PE ratio by the company's earnings per share growth (YoY TTM). As of Jul 31, 2026, Quest Diagnostics has a PE ratio of 24.42. Earnings grew at 12.6% over the TTM period ending Jun 2026. Applying the formula, this gives a PEG ratio of 1.94. PEG RATIO(1.94) = PE RATIO(24.42) / EPS GROWTH(12.6%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.